Gilde raises additional capital for healthcare service investments - Gilde Healthcare

Gilde raises additional capital for healthcare service investments

October 13, 2011

Utrecht – Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors.

“Innovative, expanding healthcare companies are in need of capital investment to support growth and this type of finance is often difficult to source from banks and governments in the current economic climate”

says Managing Partner Pieter van der Meer.

“As a value added partner providing growth capital Gilde can support the growth of various healthcare services companies.”, according to Jasper van Gorp, partner of the fund, “We are particularly focused on companies that provide quality care in a cost effective way.”

In 2010, the Gilde Healthcare Services fund invested in Stepping Stones Home & Care, a chain of small scale nursing homes for the elderly. The fund expects to announce an additional new investment in the coming weeks.

The fund complements existing Gilde Healthcare funds, which invest in companies developing medicines, diagnostic products and medical devices.

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
April 28, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
April 22, 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
April 1, 2025